Showing results (351-360 of 592) with videos related to

Sort By:
Pageof 60
Journal of Thoracic Disease|August 14, 2025
Short-term results of salvage surgery after immune and target therapies in non-small cell lung cancerMarco Chiappetta, Carolina Sassorossi, Filippo Lococo, et al.
Pathologica|October 8, 2024
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockadeAlessio Cortellini, Claudia Zampacorta, Michele De Tursi, et al.
Heliyon|December 17, 2024
Simultaneous care provision to patients with small cell lung cancer in Lazio region: Practical recommendations of a multidisciplinary groupSabrina Mariotti, Gabriele Minuti, Lorenza Landi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2024
CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung CancerMaurice Pérol, Benjamin J Solomon, Koichi Goto, et al.
Cancer|July 19, 2019
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNEEdith A Perez, Carlos Barrios, Wolfgang Eiermann, et al.
JCO Oncology Practice|April 7, 2021
Non-Small-Cell Lung Cancer: Real-World Cost Consequence AnalysisAlessandra Buja, Giulia Pasello, Giuseppe De Luca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast CancerSara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
Oncotarget|April 19, 2017
GD2 expression in breast cancerGiulia Orsi, Monica Barbolini, Guido Ficarra, et al.
BMJ Oncology|June 24, 2025
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD dataHelena M Earl, Louise Hiller, Janet A Dunn, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2021
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trialValentina Guarneri, Maria V Dieci, Gaia Griguolo, et al.
Pageof 60